SK54599A3 - Composition for the treatment of asthma, containing loratadine and a decongestant - Google Patents

Composition for the treatment of asthma, containing loratadine and a decongestant Download PDF

Info

Publication number: SK54599A3
Authority: SK; Slovakia
Prior art keywords: loratadine; pseudoephedrine; asthma; administered; use according
Prior art date: 1996-10-31

Application number

SK545-99A

Other languages

English (en)

Slovak (sk)

Inventor

Alan G Harris

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-31

Filing date

1997-10-29

Publication date

2000-08-14

1997-10-29 Application filed by Schering Corp filed Critical Schering Corp

2000-08-14 Publication of SK54599A3 publication Critical patent/SK54599A3/sk

Links

208000006673 asthma Diseases 0.000 title claims abstract description 39
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 title claims abstract description 34
229960003088 loratadine Drugs 0.000 title claims abstract description 32
239000000850 decongestant Substances 0.000 title claims abstract description 20
238000011282 treatment Methods 0.000 title claims abstract description 16
239000000203 mixture Substances 0.000 title claims description 16
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims abstract description 26
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims abstract description 23
229960003908 pseudoephedrine Drugs 0.000 claims abstract description 22
206010039083 rhinitis Diseases 0.000 claims abstract description 11
230000009325 pulmonary function Effects 0.000 claims abstract description 8
238000009472 formulation Methods 0.000 claims description 9
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 8
229940124581 decongestants Drugs 0.000 claims description 8
229960002179 ephedrine Drugs 0.000 claims description 4
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 3
-1 phenylephedrine Chemical compound 0.000 claims description 3
229960000395 phenylpropanolamine Drugs 0.000 claims description 3
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 3
239000011248 coating agent Substances 0.000 claims 2
238000000576 coating method Methods 0.000 claims 2
239000008247 solid mixture Substances 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
238000000034 method Methods 0.000 abstract description 6
239000003814 drug Substances 0.000 description 24
229940079593 drug Drugs 0.000 description 21
208000024891 symptom Diseases 0.000 description 15
239000000739 antihistaminic agent Substances 0.000 description 14
230000006872 improvement Effects 0.000 description 11
206010039085 Rhinitis allergic Diseases 0.000 description 8
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 8
201000010105 allergic rhinitis Diseases 0.000 description 8
229940125715 antihistaminic agent Drugs 0.000 description 8
239000003826 tablet Substances 0.000 description 8
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 7
229960001803 cetirizine Drugs 0.000 description 7
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
208000026935 allergic disease Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000012729 immediate-release (IR) formulation Substances 0.000 description 5
229960000351 terfenadine Drugs 0.000 description 5
206010020751 Hypersensitivity Diseases 0.000 description 4
HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 4
230000007815 allergy Effects 0.000 description 4
230000001387 anti-histamine Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000000932 sedative agent Substances 0.000 description 4
230000001624 sedative effect Effects 0.000 description 4
CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 description 3
206010011224 Cough Diseases 0.000 description 3
208000000059 Dyspnea Diseases 0.000 description 3
206010013975 Dyspnoeas Diseases 0.000 description 3
208000037656 Respiratory Sounds Diseases 0.000 description 3
206010047924 Wheezing Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
230000000172 allergic effect Effects 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
229940124630 bronchodilator Drugs 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229960001334 corticosteroids Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
230000007794 irritation Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
229960004159 pseudoephedrine sulfate Drugs 0.000 description 3
230000009467 reduction Effects 0.000 description 3
229960002052 salbutamol Drugs 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
229930182837 (R)-adrenaline Natural products 0.000 description 2
CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010070774 Respiratory tract oedema Diseases 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229940124623 antihistamine drug Drugs 0.000 description 2
229940127225 asthma medication Drugs 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960005139 epinephrine Drugs 0.000 description 2
239000000938 histamine H1 antagonist Substances 0.000 description 2
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
229960001802 phenylephrine Drugs 0.000 description 2
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
208000013220 shortness of breath Diseases 0.000 description 2
239000007787 solid Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
229960000833 xylometazoline Drugs 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
229940122236 Histamine receptor antagonist Drugs 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
208000036284 Rhinitis seasonal Diseases 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
230000008369 airway response Effects 0.000 description 1
208000028004 allergic respiratory disease Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229950000210 beclometasone dipropionate Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
231100000457 cardiotoxic Toxicity 0.000 description 1
230000001451 cardiotoxic effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
208000029771 childhood onset asthma Diseases 0.000 description 1
229940088529 claritin Drugs 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
208000027744 congestion Diseases 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
KBYGOCNIUHCOLP-MNIONDOCSA-N ethyl 4-(8-chloro-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridin-11-ylidene)piperidine-1-carboxylate;(1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 KBYGOCNIUHCOLP-MNIONDOCSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
YAHRDLICUYEDAU-UHFFFAOYSA-N methylhexaneamine Chemical compound CCC(C)CC(C)N YAHRDLICUYEDAU-UHFFFAOYSA-N 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
229960005016 naphazoline Drugs 0.000 description 1
229960002259 nedocromil sodium Drugs 0.000 description 1
229960002657 orciprenaline Drugs 0.000 description 1
229960001528 oxymetazoline Drugs 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
229960005414 pirbuterol Drugs 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
201000004335 respiratory allergy Diseases 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
229960000337 tetryzoline Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002117 triamcinolone acetonide Drugs 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK545-99A 1996-10-31 1997-10-29 Composition for the treatment of asthma, containing loratadine and a decongestant SK54599A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73966996A	1996-10-31	1996-10-31
PCT/US1997/019158 WO1998018470A1 (en)	1996-10-31	1997-10-29	Composition, for the treatment of asthma, containing loratadine and a decongestant

Publications (1)

Publication Number	Publication Date
SK54599A3 true SK54599A3 (en)	2000-08-14

Family

ID=24973307

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK545-99A SK54599A3 (en)	1996-10-31	1997-10-29	Composition for the treatment of asthma, containing loratadine and a decongestant

Country Status (21)

Country	Link
EP (1)	EP0941091A1 (ja)
JP (1)	JP2000505104A (ja)
KR (1)	KR20000052922A (ja)
CN (1)	CN1235545A (ja)
AR (1)	AR008908A1 (ja)
AU (1)	AU731756B2 (ja)
BR (1)	BR9712705A (ja)
CA (1)	CA2268546A1 (ja)
CO (1)	CO4910128A1 (ja)
CZ (1)	CZ150999A3 (ja)
HU (1)	HUP9904075A3 (ja)
ID (1)	ID23431A (ja)
IL (1)	IL129662A0 (ja)
NO (1)	NO992062L (ja)
NZ (1)	NZ335078A (ja)
PE (1)	PE11399A1 (ja)
PL (1)	PL333056A1 (ja)
SK (1)	SK54599A3 (ja)
TR (1)	TR199901003T2 (ja)
WO (1)	WO1998018470A1 (ja)
ZA (1)	ZA979731B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1205799A (en) *	1997-10-29	1999-05-17	J-Med Pharmaceuticals, Inc.	Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en)	1998-06-01	2000-10-17	Schering Corporation	Stabilized antihistamine syrup
IT1303671B1 (it) *	1998-07-28	2001-02-23	Nicox Sa	Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
PE20001070A1 (es) *	1998-09-10	2000-10-19	Schering Corp	Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
US6521254B2 (en)	1998-12-07	2003-02-18	J-Med Pharmaceuticals, Inc.	Single-dose antihistamine/decongestant formulations for treating rhinitis
HK1043945B (zh) *	1999-02-23	2005-02-08	株式会社柳韩洋行	含氯雷他定和伪麻黄碱的药物胶囊组合物
KR100505899B1 (ko) *	1999-02-23	2005-08-01	주식회사유한양행	로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
AU3924500A (en) *	1999-03-29	2000-10-16	Schering Corporation	Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
WO2001045668A2 (en) *	1999-12-20	2001-06-28	Schering Corporation	Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) *	1999-12-20	2001-07-03	Schering Corporation	Extended release oral dosage composition
EP1276502A1 (en) *	2000-04-14	2003-01-22	J-Med Pharmaceuticals, Inc.	Single-dose antihistamine/decongestant formulations for treating rhinitis
AU2001264806A1 (en) *	2000-05-25	2001-12-03	Schering Corporation	Stable liquid and solid formulations
CN1518448A (zh) *	2001-06-20	2004-08-04	��鹫˾	用于治疗鼻充血和鼻塞的抗组胺剂
RU2423979C2 (ru) *	2005-06-17	2011-07-20	АФТ Фармасьютикалз Лимитед	Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей
PL1896022T3 (pl) *	2005-06-17	2013-03-29	Aft Pharmaceuticals Ltd	Nowa kompozycja farmaceutyczna i jej zastosowanie w sposobie leczenia pacjentów z przekrwieniem śluzówki górnych dróg oddechowych
NZ573174A (en) *	2006-06-01	2012-01-12	Msd Consumer Care Inc	Sustained release pharmaceutical dosage form containing phenylephrine
WO2007143158A2 (en) *	2006-06-01	2007-12-13	Schering-Plough Healthcare Products, Inc.	Sustained release pharmaceutical formulation comprising phenylephrine
KR101540191B1 (ko) *	2014-02-24	2015-07-28	성균관대학교산학협력단	로라타딘을 포함하는 항염증용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1110397A (en) *	1964-10-02	1968-04-18	Mead Johnson & Co	Ephedrine composition
US4990535A (en) *	1989-05-03	1991-02-05	Schering Corporation	Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5407686A (en) *	1991-11-27	1995-04-18	Sidmak Laboratories, Inc.	Sustained release composition for oral administration of active ingredient
US5314697A (en) *	1992-10-23	1994-05-24	Schering Corporation	Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US5595997A (en) *	1994-12-30	1997-01-21	Sepracor Inc.	Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

1997
- 1997-10-29 CO CO97063641A patent/CO4910128A1/es unknown
- 1997-10-29 PL PL97333056A patent/PL333056A1/xx unknown
- 1997-10-29 TR TR1999/01003T patent/TR199901003T2/xx unknown
- 1997-10-29 ZA ZA9709731A patent/ZA979731B/xx unknown
- 1997-10-29 ID IDW990280D patent/ID23431A/id unknown
- 1997-10-29 WO PCT/US1997/019158 patent/WO1998018470A1/en not_active Ceased
- 1997-10-29 SK SK545-99A patent/SK54599A3/sk unknown
- 1997-10-29 HU HU9904075A patent/HUP9904075A3/hu unknown
- 1997-10-29 AR ARP970105033A patent/AR008908A1/es not_active Application Discontinuation
- 1997-10-29 KR KR1019990703790A patent/KR20000052922A/ko not_active Ceased
- 1997-10-29 CA CA002268546A patent/CA2268546A1/en not_active Abandoned
- 1997-10-29 BR BR9712705-1A patent/BR9712705A/pt not_active Application Discontinuation
- 1997-10-29 NZ NZ335078A patent/NZ335078A/xx unknown
- 1997-10-29 JP JP10520579A patent/JP2000505104A/ja active Pending
- 1997-10-29 IL IL12966297A patent/IL129662A0/xx unknown
- 1997-10-29 PE PE1997000968A patent/PE11399A1/es not_active Application Discontinuation
- 1997-10-29 CN CN97199404A patent/CN1235545A/zh active Pending
- 1997-10-29 CZ CZ991509A patent/CZ150999A3/cs unknown
- 1997-10-29 AU AU49953/97A patent/AU731756B2/en not_active Ceased
- 1997-10-29 EP EP97912874A patent/EP0941091A1/en not_active Withdrawn
1999
- 1999-04-29 NO NO992062A patent/NO992062L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20000052922A (ko)	2000-08-25
BR9712705A (pt)	1999-10-26
TR199901003T2 (xx)	1999-07-21
JP2000505104A (ja)	2000-04-25
PL333056A1 (en)	1999-11-08
AU731756B2 (en)	2001-04-05
AU4995397A (en)	1998-05-22
CZ150999A3 (cs)	1999-10-13
NZ335078A (en)	2000-10-27
IL129662A0 (en)	2000-02-29
HUP9904075A2 (hu)	2000-05-28
NO992062D0 (no)	1999-04-29
AR008908A1 (es)	2000-02-23
HUP9904075A3 (en)	2002-02-28
EP0941091A1 (en)	1999-09-15
CO4910128A1 (es)	2000-04-24
NO992062L (no)	1999-04-29
PE11399A1 (es)	1999-02-09
CN1235545A (zh)	1999-11-17
WO1998018470A1 (en)	1998-05-07
ID23431A (id)	2000-04-20
ZA979731B (en)	1998-04-29
CA2268546A1 (en)	1998-05-07

Publication	Publication Date	Title
SK54599A3 (en)	2000-08-14	Composition for the treatment of asthma, containing loratadine and a decongestant
Aaronson	1996	Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma
JP2022003100A (ja)	2022-01-11	神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
US20030236275A1 (en)	2003-12-25	Treatment methods of nasal congestion and nasal obstruction
US6432972B2 (en)	2002-08-13	Treating allergic and inflammatory conditions
KR20180033201A (ko)	2018-04-02	진해 조성물 및 방법
KR101071798B1 (ko)	2011-10-11	로플루미래스트와 포르모테롤을 포함하는 신규한상승작용성 조합물
WO2008085392A1 (en)	2008-07-17	Methods for treating nasal congestion in hepatically impaired patients
AU2001247867B2 (en)	2005-09-01	Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
JP2004534820A (ja)	2004-11-18	鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬
MXPA99003936A (en)	1999-10-14	Composition, for the treatment of asthma, containing loratadine and a decongestant
WO2002047689A2 (en)	2002-06-20	Use of cetirizine or efletirizine for preventing urticaria
JP2003509458A (ja)	2003-03-11	アレルギー状態および炎症状態の処置
AU2001247867A1 (en)	2002-01-03	Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
AU2002315357A1 (en)	2003-01-08	Antihistamines for the treatment of nasal congestion and nasal obstruction
AU2006201218A1 (en)	2006-04-27	Treating allergic and inflammatory conditions
HK1081861B (en)	2009-05-29	New synergistic combination comprising roflumilast and formoterol